Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J’s Mylanta, Mylicon Lines Return Via ‘Fixed-Term’ License With Infirst

This article was originally published in The Tan Sheet

Executive Summary

Unlike other OTC deals J&J made since McNeil Consumer Healthcare’s quality-control problems led to widespread recalls and a consent decree with FDA, the firm is not divesting the digestive health lines. Infirst will manufacture and market the products in the U.S. for an undisclosed period before the brands return to McNeil.

Advertisement

Related Content

Infirst Extends Mylanta Brand With Nighttime Product, Chewable Tablets
Infirst Extends Mylanta Brand With Nighttime Product, Chewable Tablets
Infirst Later Than Expected With Lipid-Format Ibuprofen, But On Time In Business Plan
Infirst Later Than Expected With Lipid-Format Ibuprofen, But On Time In Business Plan
J&J Includes Listerine In 20 Consumer Product Launches Planned In 2015
J&J Bit Off More Than McNeil Could Chew In 2006 Pfizer OTC Acquisition
J&J Prioritizes OTC Return With McNeil Remediation End In Sight
Chattem To Revive Rolaids Line Bought From J&J
Insight Acquires Monistat In Third Deal With McNeil For Women’s OTC Drugs
St. Joseph Aspirin Is First J&J/McNeil Divestiture From 2010 OTC Recalls

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS107543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel